Evidence map›Paper›PMID 33406139›Full record

ArticlePloS one2021

Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.

Samuel Klistorner, Michael H Barnett, Jakob Wasserthal, Con Yiannikas, Joshua Barton, John Parratt, Yuyi You, Stuart L Graham, Alexander Klistorner

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Remyelination Trials: Are We Expecting the Unexpected?Neurology(R) neuroimmunology & neuroinflammation · 2021
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Samuel KlistornerSave Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia.
Michael H BarnettBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
Jakob WasserthalDivision of Medical Image Computing (MIC), German Cancer Research Center, Heidelberg, Germany.
Con YiannikasRoyal North Shore Hospital, Sydney, New South Wales, Australia.
Joshua BartonBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
John ParrattRoyal North Shore Hospital, Sydney, New South Wales, Australia.
Yuyi YouSave Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia.
Stuart L GrahamFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
Alexander KlistornerSave Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia.ORCID 0000-0003-0361-6399
The University of Sydney · AURoyal North Shore Hospital · AUGerman Cancer Research Center · DEMacquarie University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a new single-streamline based approach to analyse diffusivity within chronic MS lesions. We used the proposed method to examine diffusivity profiles in 30 patients with relapsing multiple sclerosis and observed a significant increase of both RD and AD within the lesion core (0.38+/-0.09 μm2/ms and 0.30+/-0.12 μm2/ms respectively, p<0.0001 for both) that gradually and symmetrically diminished away from the lesion. T1-hypointensity derived axonal loss correlated highly with ΔAD (r = 0.82, p<0.0001), but moderately with ΔRD (r = 0.60, p<0.0001). Furthermore, the trendline of the ΔAD vs axonal loss intersected both axes at zero indicating close agreement between two measures in assessing the degree of axonal loss. Conversely, the trendline of the ΔRD function demonstrated a high positive value at the zero level of axonal loss, suggesting that even lesions with preserved axonal content exhibit a significant increase of RD. There was also a significant negative correlation between the level of preferential RD increase (ΔRD-ΔAD) in the lesion core and the degree of axonal damage (r = -0.62, p<0.001), indicating that ΔRD dominates in cases with milder axonal loss. Modelling diffusivity changes in the core of chronic MS lesions based on the direct proportionality of ΔAD with axonal loss and the proposed dual nature of ΔRD yielded results that were strikingly similar to the experimental data. Evaluation of lesions in a sizable cohort of MS patients using the proposed method supports the use of ΔAD as a marker of axonal loss; and the notion that demyelination and axonal loss independently contribute to the increase of RD in chronic MS lesions. The work highlights the importance of selecting appropriate patient cohorts for clinical trials of pro-remyelinating and neuroprotective therapeutics.

Indexed as

AdultAxonsChronic DiseaseDiffusion Magnetic Resonance ImagingFemaleHumansMaleMiddle AgedMultiple SclerosisNerve Fibers, MyelinatedRecurrenceWhite Matter

Identifiers

PMID33406139
PMCPMC7787472
OpenAlexW3119276788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.